Tenofovir News and Research

RSS

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women. An achievement of this magnitude could not have been possible without collaboration among governments, scientists, communities, and individual women at risk of HIV.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

UNC research to be presented at International AIDS Society conference

Dozens of UNC researchers are heading to Vienna, Austria to participate in the world's preeminent AIDS conference this week. The International AIDS Society conference brings together top scientists, advocates and government officials to discuss progress and chart a course for stemming the spread and impact of AIDS. Speakers including President Bill Clinton will address an estimated 25,000 attendees at this year's event.

15 Jul 2010

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma in patients with chronic hepatitis B. But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

25 Jun 2010

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA).

17 Jun 2010

Washington Post examines trial in Africa of long-acting vaginal ring for HIV prevention

"The first test of a long-acting vaginal ring loaded with an HIV-preventing drug has begun enrolling women in southern Africa," the Washington Post reports. The study, according to the newspaper, marks the 15th trial led by the nonprofit group, International Partnership for Microbicides, which "has helped lead the search for a discreet, woman-controlled means of protection" against the virus.

16 Jun 2010

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

News on the progress of a new trial may give new hope to patients with HIV who are dependent on anti-HIV drugs. The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from Atlanta-based, GeoVax Inc, a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines.

14 Jun 2010

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.

28 May 2010

Researchers present more findings for microbicides, prep at M2010 conference

Researchers on Monday at the International Microbicides Conference in Pittsburgh continued to present data on HIV prevention research, Reuters reports. The news service outlines several prevention methods being researched, including an intravaginal ring that over time releases two antiretrovirals - dapivirine and maraviroc - for up to a month, and a vaginal tablet that time-releases the antiretrovirals dapivirine and DS003 for up to 12 hours.

26 May 2010

Media outlets highlight studies presented at International Microbicides Conference

A study in Africa, presented Sunday at the International Microbicides Conference (M2010) in Pittsburgh, has shown that a man's risk of HIV infection doubles if his HIV-positive partner is pregnant, according to HealthDay News/U.S. News & World Report.

25 May 2010

New study indicates pregnancy can double HIV risk in men

Young women of reproductive-age are among those at greatest risk of acquiring HIV, and several studies have suggested that during pregnancy women are even more susceptible to infection.

24 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

AP examines HIV microbicides, prep research

"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.

19 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Avexa halts HIV drug trials

Melbourne-based biotech Avexa has announced the closure of its lead HIV program for apricitabine after failing to attract a licensing partner for the Phase III drug.

12 May 2010

Gilead Sciences board authorizes $5 billion common stock repurchase program

Gilead Sciences, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to $5 billion of the company's common stock through May 2013.

12 May 2010

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Gilead Sciences, Inc. announced today it has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg).

29 Apr 2010

Updates on development of Truvada and TMC278

Gilead Sciences, Inc. provided an update today on the development of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride, 25 mg).

21 Apr 2010

Tenofovir News and Research

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

UNC research to be presented at International AIDS Society conference

Antiviral therapy prevents recurrence of HCC, extends patients' lives, researchers report

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Washington Post examines trial in Africa of long-acting vaginal ring for HIV prevention

ARCA receives approval to commence enrollment of first therapeutic trial using HIV vaccine candidate

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

Researchers present more findings for microbicides, prep at M2010 conference

Media outlets highlight studies presented at International Microbicides Conference

New study indicates pregnancy can double HIV risk in men

Research on new types of anti-HIV drugs presented at International Microbicides Conference

AP examines HIV microbicides, prep research

Chimerix commences first-in-human study of CMX157 for HIV

Avexa halts HIV drug trials

Gilead Sciences board authorizes $5 billion common stock repurchase program

Gilead announces bioequivalence of Truvada in combination with Tibotec Pharmaceuticals' TMC278 NNRTI

Updates on development of Truvada and TMC278

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News